380 related articles for article (PubMed ID: 31789888)
1. Comorbidities of HIV infection: role of Nef-induced impairment of cholesterol metabolism and lipid raft functionality.
Sviridov D; Mukhamedova N; Makarov AA; Adzhubei A; Bukrinsky M
AIDS; 2020 Jan; 34(1):1-13. PubMed ID: 31789888
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux.
Cui HL; Grant A; Mukhamedova N; Pushkarsky T; Jennelle L; Dubrovsky L; Gaus K; Fitzgerald ML; Sviridov D; Bukrinsky M
J Lipid Res; 2012 Apr; 53(4):696-708. PubMed ID: 22262807
[TBL] [Abstract][Full Text] [Related]
3. Modification of lipid rafts by extracellular vesicles carrying HIV-1 protein Nef induces redistribution of amyloid precursor protein and Tau, causing neuronal dysfunction.
Ditiatkovski M; Mukhamedova N; Dragoljevic D; Hoang A; Low H; Pushkarsky T; Fu Y; Carmichael I; Hill AF; Murphy AJ; Bukrinsky M; Sviridov D
J Biol Chem; 2020 Sep; 295(38):13377-13392. PubMed ID: 32732283
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.
Mujawar Z; Rose H; Morrow MP; Pushkarsky T; Dubrovsky L; Mukhamedova N; Fu Y; Dart A; Orenstein JM; Bobryshev YV; Bukrinsky M; Sviridov D
PLoS Biol; 2006 Oct; 4(11):e365. PubMed ID: 17076584
[TBL] [Abstract][Full Text] [Related]
5. Neuro-HIV-New insights into pathogenesis and emerging therapeutic targets.
Sviridov D; Bukrinsky M
FASEB J; 2023 Dec; 37(12):e23301. PubMed ID: 37942865
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains.
Brügger B; Krautkrämer E; Tibroni N; Munte CE; Rauch S; Leibrecht I; Glass B; Breuer S; Geyer M; Kräusslich HG; Kalbitzer HR; Wieland FT; Fackler OT
Retrovirology; 2007 Oct; 4():70. PubMed ID: 17908312
[TBL] [Abstract][Full Text] [Related]
7. Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells.
Mukhamedova N; Hoang A; Dragoljevic D; Dubrovsky L; Pushkarsky T; Low H; Ditiatkovski M; Fu Y; Ohkawa R; Meikle PJ; Horvath A; Brichacek B; Miller YI; Murphy A; Bukrinsky M; Sviridov D
PLoS Pathog; 2019 Jul; 15(7):e1007907. PubMed ID: 31344124
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 reduces HIV-1 infectivity by restoration of HIV Nef mediated impairment of cholesterol efflux by apoA-I.
Lin S; Nadeau PE; Wang X; Mergia A
Retrovirology; 2012 Oct; 9():85. PubMed ID: 23067370
[TBL] [Abstract][Full Text] [Related]
9. Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation.
Hunegnaw R; Vassylyeva M; Dubrovsky L; Pushkarsky T; Sviridov D; Anashkina AA; Üren A; Brichacek B; Vassylyev DG; Adzhubei AA; Bukrinsky M
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1758-71. PubMed ID: 27470515
[TBL] [Abstract][Full Text] [Related]
10. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat.
Wang T; Yi R; Green LA; Chelvanambi S; Seimetz M; Clauss M
Cardiovasc Pathol; 2015; 24(5):279-82. PubMed ID: 26233281
[TBL] [Abstract][Full Text] [Related]
11. HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis.
Cui HL; Ditiatkovski M; Kesani R; Bobryshev YV; Liu Y; Geyer M; Mukhamedova N; Bukrinsky M; Sviridov D
FASEB J; 2014 Jul; 28(7):2828-39. PubMed ID: 24642731
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.
Anuurad E; Semrad A; Berglund L
Metab Syndr Relat Disord; 2009 Oct; 7(5):401-10. PubMed ID: 19355810
[TBL] [Abstract][Full Text] [Related]
13. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions.
Zheng YH; Plemenitas A; Fielding CJ; Peterlin BM
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8460-5. PubMed ID: 12824470
[TBL] [Abstract][Full Text] [Related]
14. Inefficient HIV-1
DeLucia DC; Rinaldo CR; Rappocciolo G
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643243
[TBL] [Abstract][Full Text] [Related]
15. Specific and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef.
Giese SI; Woerz I; Homann S; Tibroni N; Geyer M; Fackler OT
Virology; 2006 Nov; 355(2):175-91. PubMed ID: 16916529
[TBL] [Abstract][Full Text] [Related]
16. Analysis of ABCA1 and Cholesterol Efflux in HIV-Infected Cells.
Mukhamedova N; Brichacek B; Darwish C; Popratiloff A; Sviridov D; Bukrinsky M
Methods Mol Biol; 2016; 1354():281-92. PubMed ID: 26714719
[TBL] [Abstract][Full Text] [Related]
17. Nef and TNFalpha are coplayers that favor HIV-1 replication in monocytic cells and primary macrophages.
Herbein G; Varin A; Larbi A; Fortin C; Mahlknecht U; Fulop T; Aggarwal BB
Curr HIV Res; 2008 Mar; 6(2):117-29. PubMed ID: 18336259
[TBL] [Abstract][Full Text] [Related]
18. HIV: a raft-targeting approach for prevention and therapy using plant-derived compounds (review).
Verma SP
Curr Drug Targets; 2009 Jan; 10(1):51-9. PubMed ID: 19149536
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against heat shock proteins and cholesterol in HIV infection.
Füst G; Beck Z; Bánhegyi D; Kocsis J; Bíró A; Prohászka Z
Mol Immunol; 2005 Jan; 42(1):79-85. PubMed ID: 15488946
[TBL] [Abstract][Full Text] [Related]
20. Management of the metabolic effects of HIV and HIV drugs.
Brown TT; Glesby MJ
Nat Rev Endocrinol; 2011 Sep; 8(1):11-21. PubMed ID: 21931374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
